51
Background:
Broad genomic profiling (BGP) is recommended for all patients with metastatic non-squamous NSCLC to guide targeted therapy (TT) selection. As actionable alterations and matched therapies continue to expand, BGP may identify a broader group of patients eligible for TT and consequently improve pati...
Si-Da Huang, John Rothen, Jessica B. Long et al.· JCO Oncology Practice· 0 citations
37
Background:
Broad genomic profiling (BGP) is increasingly used in metastatic non-small cell lung cancer (mNSCLC), but its association with downstream treatment-related Medicare spending compared to focused gene testing (FGT) remains unclear.
Methods:
We conducted a retrospective cohort study using SEER-Med...
Akintunde O. Aremu, Jessica B. Long, John Rothen et al.· JCO Oncology Practice· 0 citations
RWE is increasingly used to support oncology SATs and holds promise as supportive or contextual evidence in regulatory decision-making and methodological limitations commonly included small sample sizes, population heterogeneity, missing or unmeasured covariates, non-aligned outcome assessments, post-hoc design, and no...
Le Su, Lei Chen, R. Mamtani et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.